The Department of Health and Human Services today announced a $354 million agreement with a private partnership to make more active pharmaceutical ingredients and generic drugs in the United States to treat patients hospitalized with COVID-19 and prevent shortages of essential medicines.

Under the four-year agreement, Phlow Corporation will partner with Civica Rx, the nonprofit generic drug company created by hospital systems and others; AMPAC Fine Chemicals; the Medicines for All Institute at Virginia Commonwealth University’s College of Engineering and others to rapidly make the active pharmaceutical ingredients and medicines using advanced manufacturing processes.

The contract can be extended up to 10 years to maintain the system and supplies.

Related News Articles

Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…